Filing Flows › Dianthus Therapeutics (DNTH) › Q2 2025
Dianthus Therapeutics (DNTH) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 7, 2025
Dianthus Therapeutics (DNTH) reported revenue of $193K for the second quarter 2025 (Q2 2025), -90% from a year earlier and -83% from the quarter before.
Dianthus Therapeutics, Q2 2025: revenue $193K (-90% year over year), net loss $31.6M, operating cash flow −$23.9M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $193K | -83% | -90% |
| Operating profit | −$34.9M | — | — |
| Net earnings | −$31.6M | — | — |
| Operating cash flow | −$23.9M | — | — |
What changed
Revenue was $193K in Q2 2025, down 90% year over year and down 83% from the previous quarter.
Operating costs exceeded revenue by $34.9M, an operating margin of -18096.9%. Total costs grew 46% against a revenue fall of 90%. The fastest-growing cost line was General & admin (+48%). The quarter ended with a net loss of $31.6M, wider than the previous quarter's $29.5M loss.
Operating cash flow was −$23.9M. Non-cash charges added back $30K of depreciation and $5.7M of share-based compensation. Working capital and other items added $2.0M. Capital expenditures of $46K exceeded it, leaving free cash flow of −$23.9M.
Questions
What was Dianthus Therapeutics' revenue in the second quarter 2025?
Dianthus Therapeutics (DNTH) reported revenue of $193K for the second quarter 2025 (Q2 2025), -90% from a year earlier and -83% from the quarter before.